58 related articles for article (PubMed ID: 25114167)
1. Comment on "Population Pharmacokinetics of Total and Unbound Isavuconazole in Critically Ill Patients: Implications for Adaptive Dosing Strategies" and "High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints".
Kong L; Alffenaar JC; Stocker SL
Clin Pharmacokinet; 2024 May; 63(5):731-733. PubMed ID: 38573478
[No Abstract] [Full Text] [Related]
2. Pharmacokinetics of isavuconazole at different target sites in healthy volunteers after single and multiple intravenous infusions.
Bergmann F; Wölfl-Duchek M; Jorda A; Al Jalali V; Leutzendorff A; Sanz-Codina M; Gompelmann D; Trimmel K; Weber M; Eberl S; Van Os W; Minichmayr IK; Reiter B; Stimpfl T; Idzko M; Zeitlinger M
J Antimicrob Chemother; 2024 May; 79(5):1169-1175. PubMed ID: 38546795
[TBL] [Abstract][Full Text] [Related]
3. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers.
Schmitt-Hoffmann A; Roos B; Heep M; Schleimer M; Weidekamm E; Brown T; Roehrle M; Beglinger C
Antimicrob Agents Chemother; 2006 Jan; 50(1):279-85. PubMed ID: 16377698
[TBL] [Abstract][Full Text] [Related]
4. Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).
Kovanda LL; Desai AV; Lu Q; Townsend RW; Akhtar S; Bonate P; Hope WW
Antimicrob Agents Chemother; 2016 Aug; 60(8):4568-76. PubMed ID: 27185799
[TBL] [Abstract][Full Text] [Related]
5. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers.
Schmitt-Hoffmann A; Roos B; Maares J; Heep M; Spickerman J; Weidekamm E; Brown T; Roehrle M
Antimicrob Agents Chemother; 2006 Jan; 50(1):286-93. PubMed ID: 16377699
[TBL] [Abstract][Full Text] [Related]
6. Demonstration of the Rationale for Therapeutic Drug Monitoring of Isavuconazole: A Case Report with a Lung Transplant Recipient.
Dvořáčková E; Zajacová A; Havlín J; Klapková E; Lischke R; Slanař O; Šíma M
Prague Med Rep; 2023; 124(4):444-448. PubMed ID: 38069649
[TBL] [Abstract][Full Text] [Related]
7. High Variability in Isavuconazole Unbound Fraction in Clinical Practice: A Call to Reconsider Pharmacokinetic/Pharmacodynamic Targets and Breakpoints.
Jansen AME; Ter Heine R; Verweij PE; Brüggemann RJM
Clin Pharmacokinet; 2023 Dec; 62(12):1695-1699. PubMed ID: 37819504
[TBL] [Abstract][Full Text] [Related]
8. Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases.
Seyedmousavi S; Verweij PE; Mouton JW
Expert Rev Anti Infect Ther; 2015 Jan; 13(1):9-27. PubMed ID: 25488140
[TBL] [Abstract][Full Text] [Related]
9. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study.
Cornely OA; Böhme A; Schmitt-Hoffmann A; Ullmann AJ
Antimicrob Agents Chemother; 2015 Apr; 59(4):2078-85. PubMed ID: 25624327
[TBL] [Abstract][Full Text] [Related]
10. Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections.
Dolton MJ; McLachlan AJ
Curr Opin Infect Dis; 2014 Dec; 27(6):493-500. PubMed ID: 25229352
[TBL] [Abstract][Full Text] [Related]
11. Isavuconazole-Animal Data and Clinical Data.
Pagano L; Cattaneo C; Quattrone M; Oberti M; Mazzitelli M; Trecarichi EM
J Fungi (Basel); 2020 Oct; 6(4):. PubMed ID: 33036295
[TBL] [Abstract][Full Text] [Related]
12. A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
Wilby KJ
Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):281-290. PubMed ID: 29101732
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.
Bellmann R; Smuszkiewicz P
Infection; 2017 Dec; 45(6):737-779. PubMed ID: 28702763
[TBL] [Abstract][Full Text] [Related]
14. Isavuconazole for the treatment of invasive aspergillosis and mucormycosis: current evidence, safety, efficacy, and clinical recommendations.
Natesan SK; Chandrasekar PH
Infect Drug Resist; 2016; 9():291-300. PubMed ID: 27994475
[TBL] [Abstract][Full Text] [Related]
15. Drug disposition before and after gastric bypass: fenofibrate and posaconazole.
Gesquiere I; Hens B; Van der Schueren B; Mols R; de Hoon J; Lannoo M; Matthys C; Foulon V; Augustijns P
Br J Clin Pharmacol; 2016 Nov; 82(5):1325-1332. PubMed ID: 27367040
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of oral isavuconazole in a patient after Roux-en-Y gastric bypass surgery.
Knoll BM
J Antimicrob Chemother; 2014 Dec; 69(12):3441-3. PubMed ID: 25114167
[No Abstract] [Full Text] [Related]
17. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
McCarthy MW; Moriyama B; Petraitiene R; Walsh TJ; Petraitis V
Clin Pharmacokinet; 2018 Dec; 57(12):1483-1491. PubMed ID: 29725999
[TBL] [Abstract][Full Text] [Related]
18. High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis.
Arsiè E; Piconi S; Iavarone M; Cozzi V; Lampertico P; Cattaneo D
Eur J Clin Pharmacol; 2018 Aug; 74(8):1089-1090. PubMed ID: 29666903
[No Abstract] [Full Text] [Related]
19. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections.
Livermore J; Hope W
Expert Opin Drug Metab Toxicol; 2012 Jun; 8(6):759-65. PubMed ID: 22530880
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
